Why has NICE said this?
NICE looks at how well treatments work in relation to how much they cost compared with other treatments available on the NHS.
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir was recommended because the benefits to people with chronic hepatitis C justify its cost.